UTHR United Therapeutics Corporation

-0.99  -1%
Previous Close 120.8
Open 120.9
Price To Book 1.87
Market Cap 5238385057
Shares 43,722,436
Volume 173,613
Short Ratio
Av. Daily Volume 355,923

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (WHO Group 3)
Phase 3 unblinding of data likely late-March or 2Q 2019.
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Pulmonary arterial hypertension (PAH)
Refusal to file Letter (RTF) issued August 31, 2017. NDA to be resubmitted 1H 2019.
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Pulmonary Arterial Hypertension
Phase 3 portion of trial continues to enroll - noted February 21, 2018.
Unituxin - DISTINCT
Small cell lung cancer

Latest News

  1. Analysts Have Mixed Opinions on United Therapeutics This Month
  2. MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
  3. United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference
  4. Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years
  5. MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results
  6. United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference
  7. Edited Transcript of UTHR earnings conference call or presentation 27-Feb-19 2:00pm GMT
  8. United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
  9. United Therapeutics Corp (UTHR) Q4 2018 Earnings Conference Call Transcript
  10. Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
  11. United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results
  12. Here's Why MannKind Rocketed Higher Today
  13. United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
  14. Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
  15. Does United Therapeutics Corporation’s (NASDAQ:UTHR) CEO Salary Reflect Performance?
  16. See what the IHS Markit Score report has to say about United Therapeutics Corp.
  17. Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress
  18. Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments
  19. The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug